These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 10368824

  • 21. [Synthetic inhibitors targeting serine and aspartic acid proteases].
    Reboud-Ravaux MC, Boggetto ND, Doucet CE, de Rosny EH, Vergely IB, Thierry NM, Amour AJ.
    J Pharm Belg; 1996; 51(3):161-4. PubMed ID: 8778349
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Design and synthesis of BACE-1 inhibitors utilizing a tertiary hydroxyl motif as the transition state mimic.
    Wångsell F, Russo F, Sävmarker J, Rosenquist A, Samuelsson B, Larhed M.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4711-4. PubMed ID: 19576765
    [Abstract] [Full Text] [Related]

  • 26. Candida proteases and their inhibition: prospects for antifungal therapy.
    Stewart K, Abad-Zapatero C.
    Curr Med Chem; 2001 Jul 15; 8(8):941-8. PubMed ID: 11375761
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Some computational aspects of theoretical anti-HIV drug design.
    Cieplak P.
    Acta Pol Pharm; 2000 Nov 15; 57 Suppl():33-6. PubMed ID: 11293258
    [Abstract] [Full Text] [Related]

  • 29. Proteases--structures, mechanism and inhibitors.
    Powers JC, Odake S, Oleksyszyn J, Hori H, Ueda T, Boduszek B, Kam C.
    Agents Actions Suppl; 1993 Nov 15; 42():3-18. PubMed ID: 8356929
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
    Gutiérrez-de-Terán H, Nervall M, Ersmark K, Liu P, Janka LK, Dunn B, Hallberg A, Aqvist J.
    Biochemistry; 2006 Sep 05; 45(35):10529-41. PubMed ID: 16939205
    [Abstract] [Full Text] [Related]

  • 32. An analysis of subdomain orientation, conformational change and disorder in relation to crystal packing of aspartic proteinases.
    Bailey D, Carpenter EP, Coker A, Coker S, Read J, Jones AT, Erskine P, Aguilar CF, Badasso M, Toldo L, Rippmann F, Sanz-Aparicio J, Albert A, Blundell TL, Roberts NB, Wood SP, Cooper JB.
    Acta Crystallogr D Biol Crystallogr; 2012 May 05; 68(Pt 5):541-52. PubMed ID: 22525752
    [Abstract] [Full Text] [Related]

  • 33. Rational design of inhibitors for drug-resistant HIV-1 aspartic protease mutants.
    Frecer V, Miertus S, Tossi A, Romeo D.
    Drug Des Discov; 1998 Oct 05; 15(4):211-31. PubMed ID: 10546067
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Human beta-secretase (BACE) and BACE inhibitors.
    John V, Beck JP, Bienkowski MJ, Sinha S, Heinrikson RL.
    J Med Chem; 2003 Oct 23; 46(22):4625-30. PubMed ID: 14561080
    [No Abstract] [Full Text] [Related]

  • 36. Identification of peptidomimetic HTLV-I protease inhibitors containing hydroxymethylcarbonyl (HMC) isostere as the transition-state mimic.
    Maegawa H, Kimura T, Arii Y, Matsui Y, Kasai S, Hayashi Y, Kiso Y.
    Bioorg Med Chem Lett; 2004 Dec 06; 14(23):5925-9. PubMed ID: 15501070
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors.
    Iserloh U, Wu Y, Cumming JN, Pan J, Wang LY, Stamford AW, Kennedy ME, Kuvelkar R, Chen X, Parker EM, Strickland C, Voigt J.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):414-7. PubMed ID: 18023580
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.